CNXU
Conexeu Sciences Inc.
NasdaqCM Healthcare United States
2,99 $US
-9.12% today
-77.12% YTD · -77.12% 1Y
4
Insider transactions
SEC Form 4 · AMF · BaFin — rolling 90 days
1
Hedge funds tracked
Latest available SEC 13F filings
42
/ 100
MIXED

Analysis Conexeu Sciences Inc. (CNXU) — Kairos Score 42/100

Composite score aggregating 8 smart money dimensions: insiders (SEC/AMF/BaFin), hedge funds, politicians & gurus, price momentum, valuation, analyst consensus, financial health, earnings momentum. The higher the score, the more favorable the institutional signals consensus.

💡 Detailed breakdown (the 8 sub-scores) available in the Premium dashboard.

About Conexeu Sciences Inc.

Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair. The company provides patented collagen-based scaffold products, including a collagen extracellular matrix (ECM) scaffold platform for use in medical aesthetics, wound care, tissue repair, facial rejuvenation, and large-volume body contouring such as face, breast, and butt volume restoration. Its CXU collagen gel is an investigational product targeting therapeutic and aesthetic indications, supporting tissue regeneration and aiming to minimize inflammation or fibrosis. The company's solutions are supported by preclinical and peer-reviewed data and are positioned as alternatives to conventional fillers or implants, with products currently investigational and pending regulatory clearance for certain applications. The company serves clients in the beauty, aesthetics, regenerative medicine, and medical sectors, including clinicians and professionals involved in facial rejuvenation, body contouring, wound care, and tissue repair. The company was founded in 2022 and is based in Reno, Nevada.

Key info

👔
CEO
Mr. Miles D. Harrison
📍
HQ
50 West Liberty Street, Suite 880, Reno, NV, 89501, United States
💰
Market cap
84 338 024,00 $US
💸
Dividend yield
0.00%

🕴️ Insider activity (90 days)

4 transactions — 0 buys and 0 sales reported by Conexeu Sciences Inc. executives.

PL
Purcell Lynn Sebastian
2026-10-15
Other
BD
Bogart David Robert
Chief Commercial Officer · 2026-09-25
Other
SJ
Sharpe Jeffrey Nathan
2026-09-14
Other

🏦 Hedge Funds

1 institutional funds report a position on CNXU in their latest SEC quarterly filing.

UBS Group AG

📰 Recent news

15 recent articles on CNXU.

🧠 What makes Kairos Insider

Beyond raw data, we aggregate and score every smart money signal to give you a unique view.

🧠

Kairos Score 0-100

8-dimension composite score: insiders · hedge funds · politicians · momentum · valuation · health · analysts · earnings.

🎯

Insider Clusters

Detection of clustered purchases or sales by several executives in the same stock.

🏦

13F Hedge Funds

Berkshire, Pershing Square, Tiger Global, Bridgewater and other reporting funds.

📈

ETF Rotations

NANC & GOP (Pelosi & Republicans), GURU (top hedge funds), ARK (Cathie Wood). See who enters and exits each week.

🔥

Google Trends

Spot marked changes in search interest around the stocks being followed.

📧

Email alerts

Create your watchlist and receive a brief of events affecting your tickers.

Companies in the same sector as Conexeu Sciences Inc.

Official sources · Public data · SEC EDGAR — Form 4 & 13F · AMF — Executive filings · BaFin — Directors' Dealings · Yahoo Finance · Alpha Vantage

🔓 Unlock the full analysis

This public page only shows a preview. The full analysis of CNXU on the Kairos Insider dashboard includes:

✅ Full Kairos Score (8-axis radar + synthesis)
✅ History of all 4 insider transactions over 90 days
✅ All 1 detected institutional funds
✅ Thematic ETFs (ARK, BUZZ, NANC, GOP, JEPI…)
✅ Hot Stocks Google Trends
✅ Available history: AUM + rotations
✅ Fundamentals (P/E, PEG, EV/EBITDA, ROE…)
✅ Financial health (Altman Z, Piotroski F)
✅ Sector peers + recent earnings
See full analysis →
Analyze other tickers for free →

Free signup · Pro €19/month or €190/year